Showing 8011-8020 of 10256 results for "".
- Physicians Report Health IT Growing But Systems Laghttps://practicaldermatology.com/news/20120921-physicians_report_health_it_growing_but_systems_lag/2459732/A new Optum Institute/Harris Interactive national survey provides insights into US consumers' willingness to view their medical records and engage with care providers online. The survey was conducted online within the United States among 1,000 US physicians, 2,870 US adults, and 400 US hospital exec
- Humira Talking Pen Launched to Educate on Self-injectionhttps://practicaldermatology.com/news/20120917-humira_talking_pen_launched_to_educate_on_self-injection/2459737/Abbott Laboratories, makers of Humira, released the Humira Talking Training Pen, available at no cost as part of the myHUMIRA patient support program (humira.com/m
- Colorescience's Diane Ranger to Receive Innovators in Dermatology Award at CSF 2012https://practicaldermatology.com/news/20120917-coloresciences_diane_ranger_to_receive_innovators_in_dermatology_award_at_csf_2012/2459738/Diane Ranger, Founder and President of Colorescience Mineral Makeup, and acknowledged inventor of mineral makeup, will receive the "Innovators in Dermatology Award" at Cosmetic Surgery F
- Direct-to-Consumer Pharmaceutical Advertising: Minimizing Risks?https://practicaldermatology.com/news/20120912-letter_to_editor_discusses_changes_in_direct-to-consumer_pharmaceutical_advertising/2459741/When prescription drugs switch to over-the-counter status, regulatory oversight of their advertising shifts to the Federal Trade Commission (FTC), potentially leading to reduced focus on warnings about risks and side effects, a new report suggests. While the FDA regulates prescription drug advertisi
- Valeant Acquires Medicis Pharmaceutical Corp. for $2.6 Billionhttps://practicaldermatology.com/news/20120904-valeant_acquires_medicis_pharmaceutical_for_26_billion/2459743/Valeant Pharmaceuticals announced an agreement to acquire Medicis Pharmaceutical for $44 per share in cash, in a deal worth approximately $2.6 billion. The transaction is expected to close in the first half of 2013 and has been approved by each company's board of directors. The combined operations w
- Plastic Surgeons Use ExtendCredit to Provide Financing Services for Patientshttps://practicaldermatology.com/news/20120830-plastic_surgeons_use_extendcredit_to_provide_financing_services_for_patients/2459744/Riverside Plastic Surgery and San Diego-based SpiritLift Plastic Surgery recently started using ExtendCredit.com, an online software platform for creating and managing in-house customer financing plans for small to mid-sized businesses. The two practices now use ExtendCredit's fully automated, onlin
- App Launched for Medical Entrepreneurshttps://practicaldermatology.com/news/20120824-app_launched_for_medical_entrepreneurs/2459746/The free Medical Entrepreneur App went live on the Apple Store this month. The app, developed by Steven M. Hacker, MD, provides healthcare providers and medical students with business intelligence and decision making tools before, duri
- Study: HA Fillers Effective for Full-face Rejuvenationhttps://practicaldermatology.com/news/20120824-study_ha_fillers_effective_for_full-face_rejuvenation/2459747/In subjects with multiple indications, full-face rejuvenation using hyaluronic acid (HA) fillers” provided effective, safe, and satisfactory results,” one of the first studies of its kind concludes. (Dermatol Surg;38(7 Pt 2):1153-61) The six-month study involved 77 subjects treated with five differe
- Suneva Medical Launches ReGenica Skincarehttps://practicaldermatology.com/news/20120809-suneva_medical_launches_regenica_skincare/2459753/Suneva Medical launched ReGenica Skincare, a three-product rejuvenation system, that contains a variety of proteins and growth factors in a serum-free solution known as Multipotent CCM Complex, says the company. In one study, ReGenica Advanced Re
- Neodyne Biosciences Announces Positive Interim Trial Results for Embracehttps://practicaldermatology.com/news/20120807-neodyne_biosciences_announces_positive_interim_trial_results_for_embrace/2459756/Neodyne Biosciences, Inc. announced positive interim results from the REFINE Trial (Scar Prevention and the Clinical Effectiveness of a Novel Mechano-modulating Polymer), a randomized, control clinical trial designed to assess the efficacy and